... Regarding What's Really Important to Get Your Drug to Patients
Sue Nemetz, founder and CEO of both Corval and The NemetzGroup, discusses bringing innovation and technology to science, being open-minded and receptive to change, and her vision for new ways to better handle the commercialization planning process.
“People think that commercial is the very end of the process. You build this drug, and the drug will sell itself. But the fact of the matter is there are multiple decisions you make along the way...”
Filmed live at Biotech Week Boston. WATCH NOW to see the entire interview. Video length: 6 minutes.
• • • • • • • • • • • • • • • • • • •
Corval is an innovative software platform that enables teams to create and manage strategic, tailored multi-year commercialization roadmaps, detailed budgets, and full resource plans.
To speak to one of our commercialization experts about your asset's journey to market, reach out to us here.
